Ethris GmbH, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, and the German Center for Infection Research (Deutsches Zentrum für Infektionsforschung, ...
Despite decades of efforts, tuberculosis remains a global health crisis, claiming over 1.3 million lives annually. In a comprehensive review published in Molecular Biomedicine, an international team ...
NEW YORK, NY AND PORRIÑO, SPAIN / ACCESS Newswire / February 26, 2025 / IAVI, a global nonprofit scientific research organization, and the Spanish biopharmaceutical company Biofabri, a subsidiary of ...
TOKYO, Feb. 2, 2026 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.39 billion (USD 8.8 million (1) ) in six R&D projects ...
“Tuberculosis is a major public health threat, tied with HIV as the leading cause of death globally among infectious diseases, with antibiotic resistance a major treatment challenge, yet we are years ...
CanSino Biologics Inc. ("CanSinoBIO"; SSE: 688185, HKEX: 06185) has been invited to share the practices of innovative vaccine at the World Government Summit 2026 (WGS 2026) which convened from ...
Mycobacterium tuberculosis (Public Health Image Library, NIAID, Image ID: 18139) Mycobacterium tuberculosis (Public Health Image Library, NIAID, Image ID: 18139) Tuberculosis (TB) is the number one ...
A highly anticipated trial of a tuberculosis vaccine yields disappointing results. A vaccine designed to protect infants against tuberculosis (TB) isn’t as effective as researchers had hoped. The ...
Tuberculosis (TB) is the world's deadliest infectious disease, killing 1.25 million people in 2023. MTBVAC is a promising vaccine candidate being evaluated in the IMAGINE trial, a large-scale safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results